Clinical Trial Search

Primary: Number of Participants Experiencing a Flare During Treatment Period 2 — 10; 21 Participants — p=<0.001

Primary: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 — 21.1; 38.9 percentage of participants — p=<0.0001

Primary: Forced Vital Capacity — 1.4; 1.4; 1.5 liters — p=0.3904

Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.32; -5.19; -5.39 VMS per day — p=<0.001

Primary: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group…

Primary: Disease Free Survival — 80.1; 79.4 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 3; 5 Participants

Primary: Ad Libitum Food and Beverage Intake (g) — 71.5; 81.9; 24.9; 33.6 g — p=0.45

Primary: Change in WOMAC A Pain — -0.81; -0.81 score on a scale — p=0.97

Primary: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. — -1.9; -1.5 score on a scale…

Primary: Number of Subjects With Adverse Events and Serious Adverse Events — 474; 19 Participants

Primary: Number of Participants Classified as Responders — 102; 15 Participants — p=<0.0001

Primary: Change in Knee Pain — -0.91; -0.89 score on a scale — p=0.94

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48 — 81…

Primary: Change in Inflammatory Lesion Count From Baseline to Week 12 — -18.1; -13.5 Lesions — p=0.043